Invalidity dossier
US 10792370
Antibody-drug conjugate
Current assignee: Shanghai Miracogen Inc
Added 10/9/2026, 12:02:03 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US 10,792,370 B2
Title: Antibody-drug conjugate
Patent number: US10792370B2
Application number: US15/550,995 (published as US20180036423A1)
Inventor: Chaohong Hu
Assignee: Shanghai Miracogen Inc. (original and current assignee)
Key dates (as listed):
- Priority date: 2015-02-17
- Filing date: 2016-02-16
- Publication date (grant): 2020-10-06
- Adjusted expiration: 2036-09-28
- Legal status listed: Active
Purpose / plain-language scope: The patent relates to an antibody-drug conjugate — a construct in which a drug is chemically bound to an antibody or immunoglobulin. Classification entries place it in A61K47/68 and related subgroups, including A61K47/68031 ("the drug being an auristatin") and A61K47/6845 (antibody targeting a cytokine, e.g., growth factors, VEGF, TNF). Other classifications reference cancer antigens and epidermal growth factor receptors (EGFR). The disclosed chemical structures depict auristatin-type drug moieties linked via maleimide-based connectors, consistent with an antibody–auristatin conjugate.
Caveats — what this excerpt does not establish:
- No claims, specification text, examples, or figures are included, so the actual claimed scope cannot be determined from this excerpt.
- The classification entries are metadata, not claim language; they do not define the invention's legal scope.
- No statement is made here about validity, enforceability, litigation, ownership changes, or prior art.
Source: https://patents.google.com/patent/US10792370/en (fetched 2026-10-09).
Generated 10/10/2026, 12:00:49 AM
Cases on file (0)
Specific litigation cases in our database that name US patent 10792370. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.